DGIdb - CITALOPRAM Drug Record

CITALOPRAM chembl:CHEMBL549 Approved

Alternate Names:

CITALOPRAM
CELEXA

Drug Info:

Drug Class	antidepressive agents, second-generation
Year of Approval	1998
FDA Approval	1998
Drug Class	small molecule
Drug Indications	Antidepressive Agents, Second-Generation

(3 More Sources)

Publications:

Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
Laje G et al., 2007, Genetic markers of suicidal ideation emerging during citalopram treatment of major depression., Am J Psychiatry
Sangkuhl K et al., 2011, PharmGKB summary: citalopram pharmacokinetics pathway., Pharmacogenet Genomics
Serretti A et al., 2011, A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression., J Affect Disord
Perlis RH et al., 2007, Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study., Arch Gen Psychiatry
Rasmussen et al., 2009, A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation., Neuropharmacology
Schloss et al., 1995, Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1., Biochemistry
Plenge et al., 2005, High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions., Neurosci. Lett.
Dugar et al., 2001, Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine., Synapse
Bareggi et al., 2007, The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders., Expert Opin Drug Metab Toxicol
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Vicentic et al., 1999, Serotonin transporter production and degradation rates: studies with RTI-76., Brain Res.
Eriksson et al., 1999, Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain., Neuropsychopharmacology
Dutta et al., 2001, Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters., J. Med. Chem.
Zhong et al., 2009, An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant., Neurosci. Lett.
Maines et al., 1999, Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain., Synapse
Coleman JA et al., 2016, X-ray structures and mechanism of the human serotonin transporter., Nature
Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Arias B et al., 2009, Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors., Pharmacogenet Genomics
Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
Sarginson JE et al., 2010, FKBP5 polymorphisms and antidepressant response in geriatric depression., Am J Med Genet B Neuropsychiatr Genet
Kirchheiner J et al., 2008, Genetic variants in FKBP5 affecting response to antidepressant drug treatment., Pharmacogenomics
Papiol S et al., 2007, Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment., J Affect Disord
Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
Antypa N et al., 2014, Genomewide interaction and enrichment analysis on antidepressant response., Psychol Med
Tsai SJ et al., 2008, Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder., Pharmacogenomics J
Garriock HA et al., 2010, A genomewide association study of citalopram response in major depressive disorder., Biol Psychiatry
Rotberg B et al., 2013, Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders., J Child Adolesc Psychopharmacol
Casamassima F et al., 2010, Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder., Am J Med Genet B Neuropsychiatr Genet
Gupta M et al., 2016, TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics., Mol Psychiatry
Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
Adkins DE et al., 2012, Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D., Transl Psychiatry
Wang P et al., 2018, Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients., Eur J Clin Pharmacol
Murphy GM Jr et al., 2013, BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression., Pharmacogenet Genomics
Musil R et al., 2013, No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression., Eur Arch Psychiatry Clin Neurosci
Yoshimura R et al., 2011, The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients., Prog Neuropsychopharmacol Biol Psychiatry
Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
Domschke K et al., 2010, Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response., Int J Neuropsychopharmacol
Demirbugen Oz M et al., 2018, The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients., Hum Psychopharmacol
Smith RM et al., 2013, Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex., Biol Psychiatry
Paddock S et al., 2007, Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort., Am J Psychiatry
Lin E et al., 2015, Genome-wide association studies in pharmacogenomics of antidepressants., Pharmacogenomics
Ji Y et al., 2011, Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics., Clin Pharmacol Ther
Amitai M et al., 2016, Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders., J Neural Transm (Vienna)

CITALOPRAM METTL21A

Interaction Score: 5.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20643483 17548750

Sources:
PharmGKB
CITALOPRAM GLDC

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21107318

Sources:
PharmGKB
CITALOPRAM TSPAN5

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26903268

Sources:
PharmGKB
CITALOPRAM COL26A1

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22760553

Sources:
PharmGKB
CITALOPRAM ERICH3

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26903268

Sources:
PharmGKB
CITALOPRAM PAPLN

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CITALOPRAM NEDD4L

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23809733

Sources:
PharmGKB
CITALOPRAM CREB1

Interaction Score: 1.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20643483 17548750

Sources:
PharmGKB
CITALOPRAM CRHR2

Interaction Score: 1.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17467808

Sources:
PharmGKB
CITALOPRAM RORA

Interaction Score: 1.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19846067

Sources:
PharmGKB
CITALOPRAM FKBP5

Interaction Score: 1.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23733030 21449676 20709156 19676097 18597649 17467808 15565110

Sources:
PharmGKB
CITALOPRAM RFK

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CITALOPRAM REEP5

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
CITALOPRAM SRP19

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
CITALOPRAM DTNBP1

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19065121

Sources:
PharmGKB
CITALOPRAM TPH1

Interaction Score: 0.83

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23733030 23221997 19590397

Sources:
PharmGKB
CITALOPRAM TPH2

Interaction Score: 0.75

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23510446

Sources:
PharmGKB
CITALOPRAM SLC6A4

Interaction Score: 0.54

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
19500602 7548008 15955412 11180498 17916059 9537821 10546982 10063489 11300876 19616061 10188639 27049939 21546862

Sources:
TdgClinicalTrial TEND
CITALOPRAM IL11

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25916525

Sources:
PharmGKB
CITALOPRAM BDNF

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29748862 23733030 23619509 22965830 21338649 20016225 19236730

Sources:
PharmGKB
CITALOPRAM GRIA3

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17898344

Sources:
PharmGKB
CITALOPRAM SERPINE1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18794724

Sources:
PharmGKB
CITALOPRAM GRK5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CITALOPRAM CACNA1C

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19388002

Sources:
PharmGKB
CITALOPRAM HTR1B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27324805

Sources:
PharmGKB
CITALOPRAM HTR2A

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30221791 23158458 19590397 17671280

Sources:
PharmGKB
CITALOPRAM GSK3B

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18195729

Sources:
PharmGKB
CITALOPRAM ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26704739 24192121 22641028 21546862 18215618

Sources:
PharmGKB
CITALOPRAM CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
CITALOPRAM CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21546862

Sources:
PharmGKB
CITALOPRAM CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
CITALOPRAM CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
CITALOPRAM EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: CITALOPRAM
- Version: 01-August-2011
Alternate Names:

CITALOPRAM Primary Drug Name

Drug Info:

Year of Approval 1998

Drug Class antidepressive agents, second-generation

Publications:
TdgClinicalTrial: CITALOPRAM
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antidepressive Agents, Second-Generation

Drug Class small molecule

FDA Approval 1998

Publications:

PharmGKB: citalopram

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Laje G et al., 2007, Genetic markers of suicidal ideation emerging during citalopram treatment of major depression., Am J Psychiatry

Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics

Rotberg B et al., 2013, Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders., J Child Adolesc Psychopharmacol

TTD: Citalopram
- Version: 2020.06.01
Alternate Names:

D0Y5DO TTD Drug ID

Drug Info:

Publications:
DTC: CITALOPRAM
- Version: 02-September-2020
Alternate Names:

CHEMBL549 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL549
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Citalopram
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Novel drug target	Established target
Trial Name	-

CITALOPRAM Drug Record

CITALOPRAM chembl:CHEMBL549 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20643483 17548750

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21107318

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26903268

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22760553

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26903268

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23809733

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20643483 17548750

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17467808

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19846067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23733030 21449676 20709156 19676097 18597649 17467808 15565110

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19065121

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23733030 23221997 19590397

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23510446

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 19500602 7548008 15955412 11180498 17916059 9537821 10546982 10063489 11300876 19616061 10188639 27049939 21546862

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25916525

Interaction Types & Directionality:

n/a

PMIDs:
20643483 17548750

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21107318

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26903268

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22760553

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26903268

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23809733

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20643483 17548750

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17467808

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19846067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23733030 21449676 20709156 19676097 18597649 17467808 15565110

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19065121

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23733030 23221997 19590397

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23510446

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
19500602 7548008 15955412 11180498 17916059 9537821 10546982 10063489 11300876 19616061 10188639 27049939 21546862

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
25916525

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29748862 23733030 23619509 22965830 21338649 20016225 19236730

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17898344

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18794724

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19388002

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27324805

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30221791 23158458 19590397 17671280

Sources:
PharmGKB

Interaction Types & Directionality:

n/a